Amylyx Pharmaceuticals, Inc.

Will Phase 3 Trial Data Change Amylyx Pharmaceuticals Stock Narrative
Simply Wall Street · 14 Oct 2026
Amylyx Pharmaceuticals (AMLX) Could Be 35% Undervalued On Phase 3 LUCIDITY Data Reveal
Simply Wall Street · 08 Oct 2026
What Amylyx Pharmaceuticals (AMLX)'s Phase 3 Data Presentation Means For Shareholders
Simply Wall Street · 07 Oct 2026
Under a preset trading plan, Amylyx Pharmaceuticals (AMLX) director sells 30,000 shares.
Stock Titan · 07 Oct 2026
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
BioSpace · 06 Oct 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.